Mustang Bio's Gene Therapy For Genetic Immunodeficiency Receives European PRIME Tag

  • The European Medicines Agency has granted Priority Medicines designation to Mustang Bio Inc's MBIO MB-107 for X-linked severe combined immunodeficiency (X-SCID) in newly diagnosed infants, also known as bubble boy disease.
  • The Company is preparing to initiate a pivotal, multicenter Phase 2 clinical trial of MB-107 in newly diagnosed patients with X-SCID at the end of Q3.
  • The PRIME program aims to optimize development plans and speed up the evaluation of promising medicines. 
  • X-linked severe combined immunodeficiency is a rare genetic disorder characterized by the absence or lack of function of key immune cells, resulting in a severely compromised immune system and death by one year of age if untreated. 
  • Price Action: MBIO shares are down 2.08% at $2.83 during the market session on the last check Monday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralBriefsgene therapy
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!